Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAVE-AA2 phase 3 trial of baricitinib in severe alopecia areata
MOH_2019-07-19_007289Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in alopecia areata comparing Placebo with Baricitinib (2 arms). Started Jun 2019; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on MOH_2019-07-19_007289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-07-19_007289.